EP2493466

AVENTIS PHARMA S.A.
Application Number
EP10782039A
Filing Date
Oct 27, 2010
Status
Granted And Under Opposition
Feb 5, 2021
Grant Date
Mar 10, 2021
External Links
Slate, Register

Biblio Summary

The patent EP2493466 was granted on Mar 10, 2021 by Aventis Pharma S.A. The patent is currently Granted And Under Opposition.

The table below shows 13 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCARE S.L.U.Aug 30, 2024INTERVENTION
MAIWALD GMBHDec 10, 2021ADMISSIBLE
STADADec 9, 2021ADMISSIBLE
VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBDec 3, 2021ADMISSIBLE
GENERICS UKJun 8, 2021ADMISSIBLE
DR. REDDY'S LABORATORIES LTD./ BETAPHARM ARZNEIMITTEL GMBHMar 31, 2021ADMISSIBLE
FRESENIUS KABI DEUTSCHLAND GMBHMar 23, 2021ADMISSIBLE
MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBHMar 22, 2021ADMISSIBLE
ZENTIVA K.S.Mar 12, 2021ADMISSIBLE
EVER VALINJECT GMBHMar 12, 2021WITHDRAWN
ACCORD HEALTHCARE LTDMar 10, 2021ADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPE LTDMar 10, 2021ADMISSIBLE
TEVAMar 10, 2021WITHDRAWN

The table below shows the patents of Aventis Pharma S.A. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3294285Cabazitaxel And Its Use For Treating CancerDec 18, 20199
EP2678011Antitumoral Combination Comprising Cabazitaxel And CisplatinJun 26, 20191